NASDAQ:WVE - Wave Life Sciences Stock Price, Forecast & News

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) announced its quarterly earnings data on Tuesday, November, 5th. The company reported ($1.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.34) by $0.14. The company had revenue of $2.93 million for the quarter, compared to analyst estimates of $6.30 million. Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Wave Life Sciences.

Wave Life Sciences will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 equities research analysts have issued 1 year target prices for Wave Life Sciences' shares. Their forecasts range from $10.00 to $65.00. On average, they anticipate Wave Life Sciences' share price to reach $25.00 in the next year. This suggests a possible upside of 218.5% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.

News stories about WVE stock have been trending somewhat positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Wave Life Sciences earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Wave Life Sciences.

Wave Life Sciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,440,000 shares, an increase of 46.4% from the January 15th total of 4,400,000 shares. Based on an average daily trading volume, of 882,200 shares, the short-interest ratio is presently 7.3 days. Currently, 24.8% of the company's shares are short sold. View Wave Life Sciences' Current Options Chain.

Some companies that are related to Wave Life Sciences include Akebia Therapeutics (AKBA), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Supernus Pharmaceuticals (SUPN), NextCure (NXTC), Dermira (DERM), Enanta Pharmaceuticals (ENTA), I-Mab (ARQT), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Opko Health (OPK), Achillion Pharmaceuticals (ACHN) and Myovant Sciences (MYOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Novavax (NVAX), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Sangamo Therapeutics (SGMO), Agile Therapeutics (AGRX), Cidara Therapeutics (CDTX) and Eyepoint Pharmaceuticals (EYPT).

Wave Life Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (2.89%), Janus Henderson Group PLC (2.34%), State Street Corp (1.40%), FMR LLC (0.61%), Point72 Asset Management L.P. (0.46%) and Spark Investment Management LLC (0.38%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Spark Investment Management LLC, State Street Corp, New York State Common Retirement Fund, Bank of America Corp DE, Platinum Investment Management Ltd. and ProShare Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

WVE stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Assenagon Asset Management S.A., Pictet Asset Management Ltd., Citigroup Inc., California Public Employees Retirement System, Amia Capital LLP, NJ State Employees Deferred Compensation Plan and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $7.85.

Wave Life Sciences has a market capitalization of $269.18 million and generates $14.41 million in revenue each year. The company earns $-146,650,000.00 in net income (profit) each year or ($5.06) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.View Additional Information About Wave Life Sciences.

The official website for Wave Life Sciences is http://www.wavelifesciences.com/.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]